Mar. 8 at 6:23 PM
$KURA Daily Chart Update:
Wedbush Cuts Price Target to
$36.00/Share From
$38.00 (still, 300% Increase from Current Levels)
KOMZIFTI -- a once-daily pill that blocks a protein (menin) that drives a specific type of leukemia (AML), targeting patients whose cancer is caused by a NPM1 gene mutation -- is just weeks into its commercial launch, Q1 2026 will be the first real revenue quarter, the company is funded through 2028, and it's sitting at a key technical breakout level (~
$9).
If the launch ramp accelerates and/or frontline Phase 3 data impresses, the re-rating could be significant.
Risk is that it's still a cash-burning biotech 💊
NFA. DYOR!
